Annual report pursuant to Section 13 and 15(d)

Business combinations - Acquisition-related costs (Details)

v3.24.0.1
Business combinations - Acquisition-related costs (Details)
$ in Thousands
12 Months Ended
Dec. 31, 2023
USD ($)
Merger with TCR2 Therapeutics Inc.  
Issuance costs incurred relating to the issuance of shares to TCR2 stockholders $ 0
TCR2 Therapeutics  
Merger with TCR2 Therapeutics Inc.  
Legal, professional and accounting fees 5,174
Bankers' fees 2,172
Total acquisition-related costs $ 7,346